These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12924604)

  • 1. Clinical applications of CD34+ cell-selected peripheral blood stem cells.
    Kawabata Y; Hirokawa M; Komatsuda A; Sawada K
    Ther Apher Dial; 2003 Jun; 7(3):298-304. PubMed ID: 12924604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and transplantation of highly purified autologous peripheral CD34+progenitor cells: purging efficacy, hematopoietic reconstitution following high dose chemotherapy in patients with breast cancer: results of a feasibility study in Japan.
    Chou T; Sano M; Ogura M; Morishima Y; Itagaki H; Tokuda Y
    Breast Cancer; 2005; 12(3):178-88. PubMed ID: 16110287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive selection of autologous peripheral blood stem cells.
    Lopez M; Beaujean F
    Baillieres Best Pract Res Clin Haematol; 1999; 12(1-2):71-86. PubMed ID: 11000984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
    Horvath N; Hahn U; Joshua D; Dyson P; Gibson J; Stevens J; Rawling T; Barrow L; Brown R; Stephens S; Gower G; Norman J; Mills B; To LB
    Intern Med J; 2004 Apr; 34(4):167-75. PubMed ID: 15086696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous and allogeneic transplantation with peripheral blood CD34+ cells: a pediatric experience.
    Watanabe T; Kawano Y; Watanabe A; Takaue Y
    Haematologica; 1999 Feb; 84(2):167-76. PubMed ID: 10091416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
    Feller N; van der Pol MA; Waaijman T; Weijers GW; Westra G; Ossenkoppele GJ; Schuurhuis GJ
    Clin Cancer Res; 2005 Jul; 11(13):4793-801. PubMed ID: 16000576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
    Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
    Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
    Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
    Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
    Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34+ subset and tumor cell quantitation by flow cytometry--step toward quality assessment of autografts in B cell malignancies.
    Johnsen HE; Rasmussen T; Knudsen LM
    Vox Sang; 1998; 74 Suppl 2():477-82. PubMed ID: 9704485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study.
    Bourhis JH; Bouko Y; Koscielny S; Bakkus M; Greinix H; Derigs G; Salles G; Feremans W; Apperley J; Samson D; Björkstrand B; Niederwieser D; Gahrton G; Pico JL; Goldschmidt H;
    Haematologica; 2007 Aug; 92(8):1083-90. PubMed ID: 17640853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
    Yang H; Robinson SN; Nieto Y; Jones RJ; Gocke CD; Lu J; Giralt SA; Jones RB; Decker WK; Xing D; Steiner D; Champlin RE; McMannis JD; Ng J; Thomas MW; Shah N; Andersson BS; Parmar S; Shpall EJ
    Cancer Res; 2011 Jul; 71(14):5040-9. PubMed ID: 21646477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation.
    Crippa F; Holmberg L; Carter RA; Hooper H; Marr KA; Bensinger W; Chauncey T; Corey L; Boeckh M
    Biol Blood Marrow Transplant; 2002; 8(5):281-9. PubMed ID: 12064366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
    Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
    Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections.
    Altès A; Sierra J; Esteve J; Martín-Henao G; Marín P; Sureda A; Briones J; Martino R; Villamor N; Colomer D; Carreras E; Garcia J; Brunet S; Montserrat E
    Exp Hematol; 2002 Jul; 30(7):824-30. PubMed ID: 12135682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries.
    Clarke E; Potter MN; Hale G; Waldmann H; Lankester A; Cornish JM; Steward CG; Marks DI; Oakhill A; Pamphilon DH
    Bone Marrow Transplant; 1998 Jul; 22(2):117-24. PubMed ID: 9707017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic transplantation of CD34+ selected hematopoietic cells--clinical problems and current challenges.
    Platzbecker U; Ehninger G; Bornhäuser M
    Leuk Lymphoma; 2004 Mar; 45(3):447-53. PubMed ID: 15160905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.